Leveraging Real-World Data for the targeted treatment of cancer
This white paper explores how RWD is transforming cancer care, using bladder cancer as a model for personalized treatment.
Having access to large, national-level biobanks with phenotype and genotype datasets for diverse ancestries, which also adhere to key regulatory and privacy standards, are critical to achieving accurate predictive models. This includes tools such as advanced polygenic risk score algorithms (PRSs), which can be used to enable preventative and personalised medicine approaches, including supporting clinical decision-making.
Download this white paper to learn about:
This white paper explores how RWD is transforming cancer care, using bladder cancer as a model for personalized treatment.
Download our white paper to see how TREs and TRUE federated analysis work in practice.
Unlock global, harmonized RWD to accelerate insights, support ECAs, and strengthen your drug development strategy with real-world success stories.